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AbstrAct
With the imminent arrival of oncology biosimilars in the 
therapeutic paradigm, stakeholders including a clinician, 
specialist nurse, patient advocate, regulator and economist 
provide their perspective on optimising the uptake of 
these new agents in the treatment of cancer. A number 
of key messages emerge, based on the discussion that 
took place during a session of the European Society for 
Medical Oncology’s Annual Congress, ESMO Madrid 2017. 
First, for successful integration of biosimilars into the 
global healthcare paradigm, informing and educating the 
full scope of stakeholders, including clinicians, nurses, 
pharmacists and patients, is primordial. Success is 
dependent on providing solid evidence and ensuring all 
voices are heard. Second, for oncology medicines, much 
can be learnt from the growing experience of approved 
biosimilars in other disease indications, with success 
stories for patients, their healthcare providers and 
healthcare budgets alike. Finally, effective sustainability of 
the impact on healthcare budgets and the redirection of 
these savings require education and transparency.
IntroduCtIon
Following the introduction of legislation 
regarding biosimilars in 2001 in the Euro-
pean Commission’s Directive 2001/83/EC, 
as of January 2018 the European Medicines 
Agency (EMA) has reviewed 59 biosimilar 
marketing authorisation applications, 39 of 
which were approved and marketed (corre-
sponding to 25 distinct biosimilars).1 The rate 
of arrival of biosimilars on the market is accel-
erating with approval of 14 new molecules in 
2017 alone, compared with no more than 
five annual approvals since 2006, when the 
first biosimilar (somatropin) was approved. 
The year 2017 also saw approval of the first 
oncology biosimilar monoclonal antibodies 
which have to date taken a backseat in this 
emerging therapeutics domain. However, the 
tide is now turning with 6 rituximab biosim-
ilars, 1 bevacizumab and 1 trastuzumab 
already approved, and of the 15 marketing 
applications currently under consideration, 3 
are for trastuzumab biosimilars.
Monoclonal antibody biosimilars repre-
sent a novel advance in the field of oncology, 
and their integration into routine clinical 
practice will contend with the same challenges 
burdening existing biosimilars in the face of 
various dogmas. A position paper published 
by the European Society for Medical 
Oncology (ESMO) in 2016 highlighted many 
of them.2 In the biosimilar setting, the tradi-
tional approach of medicines development in 
which the burden-of-proof lies at the clinical 
end of the process needs to be revisited with 
the balance shifting to comparative studies 
focusing on non-clinical and analytical func-
tional tests (figure 1). The active substance 
of a biosimilar must be similar, in molecular 
and biological terms, to the active substance 
of the reference medicinal product (RMP). 
For example, for an active substance that is a 
protein, the amino acid sequence is expected 
to be the same.3 Nevertheless, the nature of 
biologicals and hence of biosimilars, which 
are medicinal products containing a highly 
similar version of the active substance of 
their originator biological reference product, 
means that they are inherently variable; 
thus, batches may display a small degree of 
variability.
It is the manufacturers’ and regulators’ role 
to guarantee consistency, which is achieved 
by defining measurable product quality 
attributes, establishing specifications and 
specifying proven acceptability ranges.4 The 
manufacturing process of a biological is likely 
to undergo changes to improve or adapt the 
process during its life-cycle, as reflected in an 
EMA report in May 2016 that over 400 manu-
facturing changes have been authorised for 
29 monoclonal antibodies on the market.5 
Comparability is a well-established scientific 
principle used for decades by regulators to 
assess changes in the manufacturing of biolog-
icals produced by biotechnology. Similarly, 
comparability in the context of biosimilar 
development lies in a stringent head-to-head 
comparison between a biosimilar and its 
reference product in terms of structure and 
biological activity, thus ruling out potential 
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Figure 1 Distribution of data requirements for approval of a biosimilar versus a reference medicine. (PK/PD - 
pharmacokinetic/pharmacodynamic studies)
The urgency of the need to address the arrival of 
oncology biologicals cannot be downplayed. Global costs 
of oncology care reached $113 billion in 2016, a figure 
which continues to increase dramatically, and the rate 
of marketing applications and approvals of biosimilars 
continues to increase rapidly.6 Spending across the Euro-
pean Union (EU) in cancer therapeutics was €24.2 billion 
in 2016 (a 14% increase in 1 year), of which biologicals 
account for just under 40% of the total.7 Most of the top 
10 oncology medicines (in terms of sales) in the EU have 
already reached patent expiration or will by 2020. Biosim-
ilars represent an undeniable opportunity to reduce the 
burden of already overstretched oncology healthcare 
budgets, offering a significant contribution to sustain-
ability of the system. More importantly, the introduction 
of biosimilars is expected to increase availability of ther-
apeutics for patients in the EU who would not otherwise 
be treated with biologicals, mainly due to economic 
constraints, with consequent improved access to optimal 
healthcare. Here we present the perspectives of key stake-
holders, healthcare providers, patients, regulators and 
health economists, and their proposals for optimising the 
entry of biosimilars into the therapeutic paradigm.
ClInICIan’s perspeCtIve: buIldIng ConfIdenCe for 
presCrIbIng bIosImIlars
Clinicians are voicing a number of specific considera-
tions in relation to biosimilars. Underlying them is a 
clear need for scientific data and guidance, which are 
prerequisites for an accurate and informative discussion 
with their patients. A number of areas have been brought 
to the forefront. First, comprehensive information on 
the results of clinical trials conducted to support the 
marketing authorisation of biosimilars should be readily 
available, particularly with respect to the sensitive patient 
population studied and the sensitivity of the endpoints 
used. Second, data relating to extrapolation, interchange-
ability (switching and substitution) and immunogenicity 
should be addressed with clarity, to reassure both clini-
cians and patients. Finally, awareness of the pharmacov-
igilance plan (risk management plan) is a key point. This 
body of data should be transparent and easily accessible, 
with the Summary of Product Characteristics (SmPC) and 
the European Public Assessment Report (EPAR) repre-
senting an invaluable source of information.1
Extrapolation (ie, use of a biosimilar in an indica-
tion approved for the reference product but in which 
the biosimilar has not undergone comparative clinical 
testing) can be applied to biosimilars when adequate 
comparability studies for safety and efficacy of the biosim-
ilar are available in one therapeutic indication, and these 
data can be extrapolated to other approved indications 
for the reference medicine. The message must be made 
clear that extrapolation is dependent on robust scien-
tific evidence addressing all aspects of these indications, 
including mode of action, and potentially unique safety 
or immunogenicity aspects. For clinicians to be convinced 
there must be relevant analytical, preclinical, pharmaco-
kinetic, pharmacodynamic, safety and efficacy data avail-
able for the biosimilar in the evaluated indication.
Interchangeability covers both switching and substi-
tution, and falls within the remit of national legislation 
of each member state. Switching reflects the physician’s 
decision to exchange one medicine for another with 
the same therapeutic intent. It principally applies for 
replacing an originator medicine with a biosimilar, 
although the inverse situation may also apply, while 
the possibility of replacing one biosimilar with another 
is becoming increasingly pertinent. In the absence of 
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physicians, switching is an entirely feasible option.8 9 
However, it is crucial that prescribing decisions remain 
the responsibility of the treating physician, with patients 
closely involved, informed and monitored. Substitu-
tion (automatic dispensing of one medicine instead of 
another equivalent and interchangeable medicines at the 
pharmacy level without consulting the prescriber) is not 
supported by ESMO and should be avoided.
Early surveys by different groups, the National Compre-
hensive Cancer Network (NCCN), the European Crohn’s 
and Colitis Organisation (ECCO), and the Alliance for 
Safe Biologic Medicines (ASBM), reported an alarming 
lack of awareness among European physicians about 
biosimilars, along with poor practices, particularly with 
respect to labelling.10–12 Encouragingly, an updated 
ECCO survey in a small sample of healthcare providers 
published in 2016 showed substantial improvements, with 
increased awareness and confidence, notably with respect 
to extrapolation and interchangeability.13
The responsibility of building public confidence lies 
with governments (at both the EU and the national levels; 
eg, national competent authorities), regulators, manufac-
turers, as well as academia. With over 10 years of safe and 
effective use of biosimilars, the EU has the largest biosim-
ilar experience worldwide. As pioneers in this field, 
European regulators must keep in mind that compared 
with clinicians and patients, they have the advantage of 
a long history of biosimilar awareness. Their expertise is 
reassuring and certainly plays an important role in accep-
tance of these new agents. However, time is needed for 
both clinicians and patients to thoroughly understand 
this process. Interaction and collaboration among health-
care professionals and with regulators is essential for 
successful acceptance of biosimilars.
ImprovIng bIosImIlar use In the ClInIC: the CruCIal 
role of speCIalIst nurses
Specialist cancer nurses are central to optimal patient 
care, playing a dual role, directly impacting patient 
outcome, while also implementing and evaluating new 
treatments across the cancer spectrum. Overlooking 
the importance of their role in the process of intro-
ducing biosimilars will hamper our best efforts to effec-
tive outcomes. The process of a medicine reaching a 
patient from the pharmacy involves an interdisciplinary 
strategy, from selection and prescription by physicians, 
through preparation and dispensation by pharmacists, 
to receipt and delivery by nurses. Nurses are responsible 
for ensuring the patient receives the exact medicine 
prescribed (type of medicine, dose, administration route 
and timing) and can play an important role in instructing 
patients on handling different medicine presentations 
(eg, use of prefilled syringe vs an autoinjector). Their 
implication in identifying, reporting and managing treat-
ment side effects, monitoring compliance, assisting with 
adherence, and collaborating in research with long-term 
monitoring, clinical trials and data management is equally 
as important. They may also be involved in educating 
healthcare providers, developing guidelines and safety 
procedures, and providing patient information. A poor 
understanding of biosimilars for specialist nurses leaves 
room for errors and could result in a lack of nurse and 
patient confidence in the medicine, non-adherence, 
medicine errors, side effects and delays in therapeutic 
gain for patients.
The lack of uniform regulations across Europe, affecting 
the evenness of implementation of treatments, is a source 
of frustration for nurses. A recurrent barrier is the ad 
hoc nature of training for nurses on newly approved 
products, which can lead to a lack of awareness of the 
complexity and consequences of using new drug biosimi-
lars. Although studies evaluating understanding and level 
of confidence in biosimilars among healthcare providers 
are emerging, they tend to focus on the role of the physi-
cian. The NCCN survey published in 2011 demonstrated 
that a lack of familiarity and need for comprehensive 
information (scientific, economic and expert opinion) 
were more commonly reported by nurses than by physi-
cians or pharmacists.12 More extensive updated research 
and surveys will help identify and diminish the knowledge 
gaps.
the patIent’s perspeCtIve: what have we learnt and 
what Can be Improved?
The European Federation of Crohn’s and Ulcerative 
Colitis Associations (EFCCA) is an umbrella organisation 
for over 30 patient associations, and one of the first such 
groups to deal with biosimilars. Two infliximab biosimi-
lars were the first monoclonal antibodies to be approved 
by the EMA, Health Canada and several other countries 
in 2013, followed by the US Food and Drug Administra-
tion (FDA) in 2016 on the basis of clinical data from the 
phase III PLANETRA study in rheumatoid arthritis and 
the phase I PLANETAS study in patients with ankylosing 
spondylitis (AS).14 15 The PLANETRA study compared 
the efficacy and safety of the infliximab orinator to its 
biosimilar, in active rheumatoid arthiritis patients with 
inadequate response to methotrexate treatment, whereas 
the PLANETAS study compared the pharmacokinetics, 
safety and efficacy of the two medicinal products to 
patients with active AS.14 15  Approval in indications other 
than those studied, including Crohn’s disease and ulcer-
ative colitis, was by extrapolation and led to some initial 
concern by healthcare professionals as different mecha-
nisms of action could be involved.16 17 However, it is note-
worthy that by 2016 the full label (ie, including all indica-
tions) had been approved by all major regulatory bodies 
(EU, FDA, Canada, Japan and Australia), suggesting a 
high level of agreement on the total scientific evidence 
presented by the applicant, thus justifying extrapolation. 
This concept is pivotal in understanding the development 
paradigm of biosimilars and—although counterintui-
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with autoimmune disease and be possible to extrapolate 
to oncology indications without further clinical data.18
In 2014, an EFCCA survey on biosimilars carried out 
in over 1000 European patients highlighted a number 
of important outcomes.19 First—and very importantly—
many patients were unaware of biosimilars, while those 
who had heard of biosimilars expressed strong scepti-
cism over extrapolation. While interchangeability was 
considered acceptable under certain conditions, trans-
parency to properly understand their medication was 
paramount. Finally, traceability was noted as a concern, 
with patients expressing confusion over product naming 
and batches. Patients wish to be well informed about the 
choice of their treatment (requesting more than a brief 
talk with a treating physician or a consensus paper) and 
to be involved in the decision-making process. Progress 
has been made, with the European Parliament holding 
a Patient Advocacy and Safety Conference in November 
2016 to explore biologicals and biosimilars with patient 
advocate groups and how different policies and prac-
tices across Europe impact patients.20 Patients raised 
concerns over sufficient patient education, extrapolation, 
switching, traceability, informed consent and access to 
information.
Patient advocacy has a critical role to play in engi-
neering acceptance of biosimilar use, and oncology 
patient advocates can learn much from the experience of 
the EFCCA and other inflammatory bowel disease groups. 
Advocacy is important to build awareness among patient 
communities over issues impacting access to biologicals 
and biosimilars, and also contributes to patients’ basic 
understanding of the science and issues surrounding 
these agents. Advocates must provide training on effec-
tive advocacy and communication strategies to raise 
awareness and understanding among key policy makers. 
The different geographical locations of advocacy groups 
offer an opportunity to network and extend sharing of 
best practices.
provIdIng regulatory transparenCy for bIosImIlars
Providing the public with clear, unbiased and transparent 
information on the benefits and risks of the medicines it 
evaluates is an essential role of the EMA. The main objec-
tive of this information is to reflect the rationale under-
pinning the decision by EMA’s scientific committees that 
the benefits of a given medicine outweigh its risks. Appro-
priate information must be—and is—addressed to two 
distinct audiences, healthcare professionals and patients. 
For the former group information is available from three 
sources. The EPAR contains the Assessment Report, a 
thorough summary of the analytical, preclinical and clin-
ical data obtained in the comparability exercise of the 
biosimilar with its RMP. It also reflects input from scien-
tific committees, including the Committee for Medicinal 
Products for Human Use (CHMP) and the Pharmacovigi-
lance Risk Assessment Committee (PRAC), which led to a 
positive benefit risk assessment. The SmPC is also publicly 
available on the EMA website, is part of the EPAR, and 
provides information on prescribing, posology, dosing, 
safety, efficacy and conditions of use of the medicine. 
As the biosimilar and the RMP are different versions of 
the same active substance, which will be used in the same 
way (posology and route of administration of the biosim-
ilar must be the same as those of the RMP),3 the SmPCs 
should be largely identical.21–23 Finally, emerging safety 
information obtained postmarketing is communicated to 
healthcare professionals via the EMA’s safety communi-
cations. A lay audience equivalent to each of these three 
information sources is made available to patients: the 
EPAR summary for the public, the patient information 
leaflet and a specific section for patients within the EMA 
safety communications.
Since the approval of docetaxel by the EMA in 1995, 
major improvements have been seen in the transparency 
of information for both professionals and patients. At 
that time, a simple statement was provided affirming the 
CHMP’s decision that the data were sufficient to support 
a positive recommendation. Today, the EPAR contains a 
multipage comprehensive report detailing discussions on 
all aspects of the comparability exercise (quality, preclin-
ical and clinical data), that is, PK/PD (pharmacokinetics/
pharmacodynamics) and phase III clinical results with a 
justification for extrapolation and discussion on the posi-
tive benefit–risk balance also in the extrapolated indica-
tions. Furthermore, these changes are mirrored in the 
level of information provided for patients.
The introduction of biosimilars to the array of agents 
the EMA is called on to approve generated misunder-
standings in terms of their clinical development and 
misconceptions, revealing new communication chal-
lenges. Healthcare professionals and patients have voiced 
a clear need for unbiased information to help them make 
informed treatment decisions. Conveying the biosimilar 
concept is complex and challenging, due mainly to a 
generalised lack of understanding of the development of 
biological/biotechnological medicines, to the challenge 
of convincing audiences that the same standards of safety 
and efficacy apply without the need for repeating clinical 
studies in each disease indication, and because of the 
difficulty of balancing precise regulatory concepts with 
public-friendly messages. There is an important need to 
address these communication challenges, given on the 
one hand the increasing number of biosimilars reaching 
the market, and on the other that misconceptions could 
hinder the widespread acceptance and uptake of biosim-
ilars. This could, in turn, impact the sustainability of our 
healthcare systems.
The EMA joined forces with the European Commission 
to provide clear and comprehensible information that is 
scientifically accurate and also contains sufficient regu-
latory references to assure proper regulatory review and 
oversight. The result was the publication in April 2017 of 
the Information Guide for Healthcare Professionals on 
Biosimilars in the EU, which is publicly available.21 In 
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box 1 Content of the ema Information guide for 
healthcare professionals on biosimilars in the eu21
 ► Key principles of biologicals, biosimilars and reference medicines.
 ► Why biosimilars cannot be considered generic medicines.
 ► Development and approval of biosimilars in the EU (comparability, 
extrapolation, immunogenicity, safety, traceability).
 ► Data in the EU prescribing information and EPAR.
 ► Rigorous standards for approval.
 ► Implications of the availability of biosimilars.
 ► Interchangeability, switching and substitution: EU definitions, EMA 
vs member state responsibility.
 ► Communicating with patients on biosimilars.
EMA, European Medicines Agency; EPAR, European Public Assessment Report; 
EU, European Union.
from all EU member states, EMA’s Biosimilar Medicinal 
Products Working Party (BMWP), healthcare profes-
sionals, patients and consumers also collaborated on the 
document. ESMO also provided valuable contributions 
with input from experts and clinicians to ensure the 
guide also addresses information needs for the oncology 
community. The Information Guide summarises the 
major issues concerning biosimilars (box 1), is written 
with simple language and a minimum of regulatory 
jargon, and includes illustrations and tables. To ensure 
widespread access, a dissemination strategy was put in 
place via a variety of channels, including email, online 
access, social media, professional journals, the EU Regu-
latory Network, learned societies, European medical/
pharmacy students and faculty associations. Feedback 
will be monitored at the EMA’s Healthcare Professionals’ 
Working Party meetings.
ImpaCt of onCology bIosImIlars on the sustaInabIlIty 
of healthCare systems
With multiple biosimilars for rituximab, trastuzumab and 
bevacizumab (representing the top 3 oncology biolog-
ical medicines) already approved by the EMA, and many 
more currently under review, integration of biosimi-
lars into oncology therapeutic management represents 
an unprecedented opportunity for savings. Economic 
advantages with biosimilar use can be expected within 
a relatively short-term period, with economic modelling 
showing that the introduction of biosimilars for the top 
3 oncology agents is estimated to add up to as much as 
€2 billion in savings across all European markets in 2021 
alone.7 Significant cross-country (and within-country) 
variability can be expected, influenced by the awareness 
and acceptance of healthcare providers and patients 
(thus impacting prescription), and national negotiations 
in terms of pricing and substitution guidelines.
The balance of the timing and impact of biosimilars on 
the market (and hence on healthcare budgets) hinges 
on three main criteria: the availability of evidence (for 
safety and efficacy from both regulatory and real-world 
perspectives), effective communication of this evidence 
by educating healthcare providers and patients, and 
incentive for investment in terms of an adequate prospect 
of profit.
Competition for developing biosimilars is increasing, 
influencing the dynamics of the market-place. The chal-
lenge is to maintain a vigorous market and balance it with 
the race to obtain the lowest possible prices. The notion 
of sustainability is increasingly important, given that low 
prices may be unsustainable for any length of time. It is 
important to avoid the pitfall of one biosimilar capturing 
a large share of the market with major cost cuts, leaving 
less room for manoeuvre for newly arriving biosimilars.
the sCandInavIan experIenCe: a real-lIfe experIment 
IntroduCIng a bIosImIlar
Since 2001, Stockholm has benefited from the ‘Kloka 
Listan’—the ‘Wise List’, an annual publication by the 
Stockholm Pharmaceutical Committee listing recom-
mended essential medicines used for common diseases 
in patients in the Stockholm metropolitan region. It has 
gained international interest,24 with much of its success 
attributed to the collaborative approach used to compile 
it. Around 250 healthcare professionals (mainly physi-
cians but also pharmacists and pharmacologists) and 
expert committees in different indications meet to discuss 
the efficacy, safety and medical suitability of medicines 
according to agreed guidelines.
A similar approach was implemented with the arrival 
of the first biosimilar on the Swedish market. Infliximab, 
an antitumour necrosis factor-α for treating autoimmune 
diseases, was introduced in Norway in January 2014 
and then in Sweden and Denmark a year later. In early 
2015, annual tenders in Norway and Denmark obtained 
a substantial discount (approximately 70%) off the orig-
inator price. In Denmark, an aggressive approach was 
used to push physicians to prescribe the biosimilar. This 
strategy proved successful from both a health economics 
perspective with very rapid uptake of its use, and clinically 
with an absence of reported adverse reactions, although 
it was largely unpopular with Danish physicians and 
patients. On the other hand in the Stockholm region, 
following apprehension and concern voiced by both 
doctors and patients, notably in terms of insufficient data, 
a consensus decision was made in 2014 at a regional level 
that doctors would not be obliged to switch from the orig-
inator to the biosimilar, with prescription maintained as a 
choice. The aim was that by foregoing a short-term finan-
cial gain, confidence in biosimilars and their role in the 
therapeutic portfolio would evolve organically, allowing 
subsequent biosimilars to be introduced more rapidly. 
As a result, infliximab uptake was considerably slower in 
the Stockholm region than in Norway and Denmark from 
its introduction in 2015 and throughout 2016, initially 
being primarily used in infliximab-naïve patients, repre-
senting a relatively small proportion of the market. Other 
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In April 2016, a meeting was held in preparation for 
the next Stockholm tender in January 2017, bringing 
together expert subcommittees from a wide range of 
indications as well as hospital department heads. Two 
options were proposed, maintaining ongoing patients 
on originator and requesting the biosimilar for inflix-
imab-naïve patients only, or requesting only the biosim-
ilar. After extensive discussion, the consensus was for a 
single product tender, which ultimately also obtained a 
70% price reduction. The result was that within approx-
imately 4 months, the biosimilar had captured approxi-
mately 90% of the market share. Patients were informed 
by a letter in clear layperson language explaining the 
switch to a similar approved product; less than 1% of 
patients subsequently chose to switch back to the origi-
nator product. Once again, similar strategies have been 
used in other regions of Sweden. Sweden—and Stock-
holm in particular—has benefited from the experience 
of its neighbours and their collaborative approach has 
proven highly effective, with the second biosimilar (for 
etanercept) that entered the Swedish market rapidly 
occupying a large portion of the market within a year of 
its introduction.
lessons learnt
Today several actions need to be coordinated to effec-
tively move forward towards successful uptake of biosimi-
lars in the field of oncology. Building confidence among 
all stakeholders is paramount and requires a multidisci-
plinary strategy. Currently the focus is on clarifying the 
science of approving biosimilar medicines from an alter-
native angle, moving the burden-of-proof from clinical 
efficacy and safety to comparability on an analytical and 
preclinical level. Investing in ongoing interdisciplinary 
and standardised education to improve scientific under-
standing, establishing collaborations between groups, 
and involving the patients and healthcare professionals 
in these processes will undoubtedly raise the standard of 
care. Education needs to intervene at all levels, involving 
physicians, nurses, pharmacists and patients. Guid-
ance from key players, notably regulatory bodies and 
national representatives, is critical to successfully convey 
the message of the value of biosimilars. The Informa-
tion Guide developed by the EMA and the European 
Commission21 goes a long way towards addressing many 
of these aspects. Building collaborations and cross-spe-
cialty relations will allow newcomer biosimilars to benefit 
from previous experience. The ECCO position paper 
published in 2017 provides guidelines for implementing 
this process.25 Collaborations such as that established in 
Sweden for the introduction of biosimilars, emphasising 
open discussion between all categories of healthcare 
professionals as well as patients, provide a role model 
for a successful approach. Educating patients is essential 
to dispel concerns about biosimilars and to equip them 
to participate in decision-making and policies.26 This 
involves obtaining a consensus among patient groups 
to ensure credibility among physicians, educating and 
motivating patient groups, involving patients in clin-
ical research and creating scientific advisory commit-
tees within patient groups. Strong collaborations in the 
patient community and at the EU, national and regional 
levels will help ensure visibility.
Analysis of real-life safety and efficacy data will feed 
confidence. To optimise this process and ensure smooth 
data collection, a number of logistical challenges need 
to be addressed, including the development of coherent 
registries (collecting the same data variables to allow 
optimal data exploitation) from a range of settings (real-
life, clinical trials, compassionate-use, observational 
studies), robust and accessible pharmacovigilance data 
systems, and a marked improvement of interoperability of 
systems at both an international and national level. Exam-
ples for best practices exist, such as DANBIO, the Danish 
registry for patients with rheumatic diseases receiving 
biological therapies in which almost all patients are 
entered, and positive switch data are readily available to 
healthcare professionals, thus contributing to increasing 
the confidence in biosimilars.
The introduction of biosimilars to the market needs 
to be carefully controlled to ensure adequate prospects 
of profit for manufacturers to invest. Another important 
confidence driver for ensuring the value of using biosim-
ilars lies in the need for transparency and planning in 
terms of the economic outcomes of introducing biosimi-
lars into the therapeutic equation. Healthcare providers 
need to be educated on the implications of prescribing 
different medicines on the healthcare system costs. Wise 
use of the cost savings and informing the public as to the 
reallocation of these ‘gained’ funds to support sustain-
ability of the healthcare system is needed at both a global 
and local hospital level.
It is important to identify knowledge gaps and educa-
tional needs among all healthcare providers, and patients 
and surveys may help clarify the status of progress and 
direct us towards areas needing more attention. Two 
specific areas of focus include switching and extrapola-
tion. For now, the public jury is out over switching; from 
a regulatory standpoint, there are no major obstacles; 
however, confidence from physicians and patients must 
improve. Evidence-based standards and guidelines to 
ensure patient safety in the context of switching between 
a reference product and its biosimilar(s) are needed.27 
Studies such as the prospective randomised controlled 
NOR-SWITCH study demonstrating the safety of 
switching from the originator to the infliximab biosimilar 
will help increase confidence,28 and equivalent prospec-
tive studies in oncology should be anticipated. In the 
NOR-SWITCH EXTENSION trial—a 26-week open label 
extension trial—concerning the inflammatory boweldis-
ease (IBD) subgroup, the authors concluded there 
were no differences between the maintenance group 
and the switch group regarding disease worsening, thus 
supporting previous conclusions.29 Extrapolation always 
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is not automatically granted. Extrapolation needs to be 
supported by all of the scientific evidence (the totality 
of evidence) generated in robust comparability studies, 
structural (quality) and functional (non-clinical and 
clinical data),30 31 with an emphasis on quality. Addi-
tional supportive studies may be requested. Healthcare 
providers must be reminded that all approved indications 
of a medicine are granted based on scientific evidence. In 
the case of biosimilars the totality of evidence is pivotal 
for approval, with confirmation in at least one sensitive 
patient population, which can then be applied to several/
all indications.32 This reduces the need to repeat clinical 
trials for all indications, thus avoiding subjecting patients 
and healthy volunteers to unnecessary clinical trials, 
along with the associated costs.
In conclusion, with a rapidly increasing range of biolog-
ical products and well-informed healthcare professionals 
and patients, biosimilars represent one of the ways 
forward to obtain sustainability and broaden access to 
biologicals in regions where their uptake is still low due 
to economic issues. Physicians will make decisions based 
on what is best for their patients, but to ensure that an 
informed decision on all treatment options is reached, it 
is crucial that all stakeholders—prescribers, pharmacists, 
nurses and patients—are adequately informed.
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